Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company completed and reported results from the FIT Phase 3 clinical program of fostamatinb in chronic immune thrombocytopenia, or ITP
. Rigel is also conducting a Phase 2 clinical trial with fostamatinib in autoimmune hemolytic anemia (AIHA)
and a Phase 2 clinical trial in IgA nephropathy (IgAN)
. In addition, Rigel has two oncology product candidates in development with partners BerGenBio AS
(Phase 2) and Daiichi Sankyo
Recent NewsMore »
|04/27/17||Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States|
|SOUTH SAN FRANCISCO, Calif., April 27, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Tavalisse™ for the company's investigational product candidate, fostamatinib disodium, an oral spleen tyrosine kinase (SYK) inhibitor. In addition, Rigel has applied to the U.S. Patent and Trademark Office to obtain federal registration of the Tavalisse mark.
The name Tavalisse (pr... |
|04/25/17||Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results|
|SOUTH SAN FRANCISCO, Calif., April 25, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2017 financial results after market close on Tuesday, May 2, 2017. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.
Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (... |
|04/17/17||Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP|
|SOUTH SAN FRANCISCO, Calif., April 17, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fostamatinib in patients with chronic and persistent immune thrombocytopenia (ITP).
"This NDA submission in support of fostamatinib in ITP is a major milestone in bringing new treatment options to patients suffering from this disease," said Raul Rodriguez, Rigel's president a... |
Upcoming EventsMore »
|Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.|